Researchers discovered that an immunotherapy, called anti-CTLA-4, mobilizes microglia against glioblastoma as it causes CD4+ T cell infiltration of the brain. A study led by Salk Institute (CA, USA) ...

CS2009是一款同时靶向PD-1、CTLA-4和VEGFA的药物，具有潜在同类首创的作用机理。 CS2009拥有平衡的抗PD-1和抗CTLA-4亲和力，可以同时结合PD-1、CTLA-4及VEGFA ...

Interestingly, CTLA-4 knockout mice and mice that lack expression of CTLA-4 just in T REG develop fatal, early-onset lymphoproliferative disease. 1,4 In addition, expression and signaling of CTLA ...

Replimune's BLA submission and promising pipeline drugs are set to impact the global melanoma therapeutics market. Read more ...

AI-081 is a differentiated bispecific antibody with robust cooperative interactions between PD1 and VEGFDosing of first patient in BIPAVE-001 ...

The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 ...

China’s NRDL includes Akeso’s two bispecific antibody drugs, cadonilimab & ivonescimab: Hong Kong Friday, November 29, 2024, 10:00 Hrs [IST] Akeso, Inc., a leading biopharmace ...

a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4; and HBM1020, human monoclonal antibody generated from harbour mice platform targeting B7H7. The company is also ...

Designed to target PD-1, CTLA-4, and VEGFA, CS2009 shows superior anti-tumor activity and potential applicability across various cancer types. The company anticipates initiating first-in-human ...